The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake

ChemMedChem. 2021 Mar 3;16(5):869-880. doi: 10.1002/cmdc.202000824. Epub 2020 Dec 11.

Abstract

The l-type amino acid transporter 1 (LAT1, SLC7A5) imports dietary amino acids and amino acid drugs (e. g., l-DOPA) into the brain, and plays a role in cancer metabolism. Though there have been numerous reports of LAT1-targeted amino acid-drug conjugates (prodrugs), identifying the structural determinants to enhance substrate activity has been challenging. In this work, we investigated the position and orientation of a carbonyl group in linking hydrophobic moieties including the anti-inflammatory drug ketoprofen to l-tyrosine and l-phenylalanine. We found that esters of meta-carboxyl l-phenylalanine had better LAT1 transport rates than the corresponding acylated l-tyrosine analogues. However, as the size of the hydrophobic moiety increased, we observed a decrease in LAT1 transport rate with a concomitant increase in potency of inhibition. Our results have important implications for designing amino acid prodrugs that target LAT1 at the blood-brain barrier or on cancer cells.

Keywords: amino acids; blood-brain barrier; drug delivery; membrane proteins; prodrugs.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Brain / drug effects*
  • Brain / metabolism
  • Dose-Response Relationship, Drug
  • Humans
  • Ketoprofen / chemistry
  • Ketoprofen / pharmacology*
  • Large Neutral Amino Acid-Transporter 1 / metabolism*
  • Molecular Structure
  • Particle Size
  • Prodrugs / chemistry
  • Prodrugs / pharmacology*
  • Structure-Activity Relationship

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Large Neutral Amino Acid-Transporter 1
  • Prodrugs
  • SLC7A5 protein, human
  • Ketoprofen